Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Infusion of Biotechnology Into Cannabis Market Leads to Booming Growth

CannabisNewsWire Editorial Coverage: The tremendous growth of the licensed cannabis market has naturally led to an increase in research in this area. A number of specialist biotech companies have emerged, creating innovative cannabinoid applications. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) has developed technology to improve the palatability and speed of absorption of cannabinoid therapeutics, leading to a range of licensed products and related patents. Plant biotechnology company 22nd Century Group, Inc. (NYSE American: XXII) is altering the level of active ingredients in both cannabis and tobacco, allowing new strains to be grown for medical and other purposes. GW Pharmaceuticals plc (NASDAQ: GWPH) has developed extensive expertise in research, regulatory allowances and manufacturing, creating a pipeline of products for illnesses including epilepsy and multiple sclerosis. INSYS Therapeutics, Inc.  (NASDAQ: INSY) is creating drugs for previously unmet patient needs, researching novel systems to deliver active ingredients as effectively as possible. Even rare illnesses are being addressed by this research boom, with Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) focusing on neurological disorders, including fragile X syndrome and Tourette’s syndrome.

The Importance of Cannabis Biotech

As the cannabis market grows, biotechnology is taking an increasingly important place in that market.

From a position of almost global illegality 20 years ago, cannabis is evolving into a multibillion-dollar legal industry. Shifting social attitudes have led to the legalization of licensed medical cannabis in more than half of the United States and in many other countries around the world. A handful of countries are also now moving to legalize the recreational use of cannabis, accelerating the growth of the industry. Because of these changes, much of the public’s attention has been on social and legal developments.

This focus ignores the groundbreaking work emerging from cannabis research and design departments. Biotechnology has become a crucial part of the cannabis market as researchers explore new applications for the plant’s active ingredients and new ways of delivering drugs derived from them. This has led to exciting efforts in tackling opioid addiction, helping brains age more healthily and managing the symptoms of Parkinson’s disease, just to name a few. The medical application of cannabis is becoming more sophisticated, and the cannabis biotech sector is growing in both power and profitability.

Business-to-Business Biotech

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has taken an important place in this part of the market.

Lexaria is a research-driven company whose work focuses on improved drug delivery systems. This expertise started with DehydraTECH™, a technology that has been proven both in the laboratory and the market to improve the consumption of beneficial compounds.

Many of these compounds are lipophilic, meaning they are fat soluble. They taste and smell unpleasant, are poorly absorbed by the body, and are vulnerable to being broken down by the stomach and metabolized away by the liver. This leads to poor bioavailability, or how much of the compound the body can use. Smoking, vaping and added chemicals have all been used to try to alleviate this, but DehydraTECH offers a different solution. The lipophilic compound is combined with fatty acids in a process that makes it nearly odorless and tasteless while protecting it from hostile stomach conditions to increase both its speed of delivery to appropriate biological systems and rate of absorption.

This technology can also be applied to vitamins, supplements, nicotine and pharmaceuticals. And it is particularly applicable for both cannabis and tobacco-derived drugs because it allows patients to benefit from the active ingredients without having to smoke, thereby reducing harmful side effects from smoking. By increasing the efficacy of drugs, the technology also reduces quantities needed, cutting costs and minimizing drug-related side effects.

Lexaria has focused on licensing out its technology utilizing a business model similar to that used by software companies. Through licensing agreements with companies in Canada, the United States and beyond, Lexaria’s technology could benefit patients around the world. Meanwhile, the company itself can stay focused on biotechnology research without the burden of expensive commercial operations.

Piling Up the Patents

The result is a company that has developed a significant volume of intellectual property in its short history — and that volume continues to grow. Currently Lexaria has 15 patent applications filed in the United States and over 30 pending in more than 40 countries, plus two patents granted for cannabinoid delivery in the United States and one granted in Australia. With researchers continuing to refine the DehydraTECH system, the patents keep piling up.

In March the company received a Notice of Allowance from the United States Patent and Trademark Office relating to substances that improve the taste and absorption of cannabinoids  (http://cnw.fm/A14bT). This is expected to lead to the granting of yet another U.S. patent soon to add more protected commercial values for Lexaria’s partnered companies.

The company is also exploring the use of DehydraTECH in the absorption of drugs through the skin. Lexaria has recently filed a new patent to improve the speed and quantity of absorption for transdermal applications (http://cnw.fm/4sYzF). A recent breakthrough in testing discovered that DehydraTECH can double the transdermal absorption of cannabidiol  compared with leading commercial alternatives. This will allow the company to newly license its technology to create improved patches, creams, cosmetics and more.

In addition, the company’s work has been enhanced through an R&D agreement with the Canadian government’s National Research Council. This agreement is expected to result in a better understanding of how Lexaria’s technology works, leading to more agreements with other businesses.

It is ironic that this technology was developed for the cannabis industry but has already received patent protection for many other commonly used drugs. Anti-inflammatory drugs, vitamins and nicotine could all be deployed using Lexaria’s disruptive technology. Supplements, pain relief and smoking-cessation or smoking-alternative nicotine products are all possible as a result of Lexaria’s research. To this end, the company recently commenced a study into nicotine absorption (http://cnw.fm/DLo69). Who would have thought that cannabis research might lead to broader biotechnology applications that could benefit non-cannabis consumers?

Immediate Benefits

Cannabis is a fast-growing sector; moving quickly to develop and deploy new technology is important. Every year sees new areas of the world opening up to licensed cannabis use, as well as new products being commercialized to make the most of this market. Companies are rushing to develop the products that will fill this developing market.

The sooner these products can be patented, the sooner they can be brought to market, and Lexaria may again have a distinct first-mover advantage in this area. With patents filed and backdated to 2014 for a range of related technologies in dozens of different jurisdictions, the company may soon be able to commercialize its systems around the globe. Lexaria’s IP is steadily increasing, covering more effective bio-delivery of medical cannabis, recreational cannabis and over-the-counter pain remedies such as aspirin and ibuprofen. Through licensing to partner companies, Lexaria may soon be using this technology to drive value and prove the advantage of its systems worldwide.

The Broader Picture of Cannabis Biotech

Of course, Lexaria isn’t the only company applying biotechnology to cannabis in a search for new products. A wide range of research is leading to a diverse range of innovations set to disrupt this exciting sector.

Plant biotech company 22nd Century Group (NYSE American: XXII) is focused on changing the chemical composition of plant strains. Initially working on tobacco, the company has developed plants that have both very low and very high levels of nicotine. This broad range can be used to help smokers quit or reduce harm to those still smoking. Through its Botanical Genetics subsidiary, 22nd Century Group is turning its attention to controlling the level of active ingredients in cannabis. This has potential not only to create more effective medicines but also to support industrial hemp growth by removing active ingredients so that the plant can more easily be farmed for fibers and food.

Based in the United States and the United Kingdom, GW Pharmaceuticals plc (NASDAQ: GWPH) is a developer of cannabinoid-based medicines. Twenty years of work have given the company extensive expertise in research, regulations and manufacturing, allowing it to manage the whole pipeline, from research inspiration to a complete product. Its medicines are used in tackling the symptoms of epilepsy and multiple sclerosis, with more in the research pipeline.

Like Lexaria, INSYS Therapeutics (NASDAQ: INSY) is focused on producing new cannabinoid medicines and delivery systems to make better use of the drugs. The company is also studying how to use the newly unleashed potential of cannabis to create drugs for previously unmet patient needs. New drugs developed by the company’s researchers may help medical professionals support patients who previously lacked effective treatment. Drugs in the pipeline include an oral treatment for treating spasms in children.

Zynerba Pharmaceuticals (NASDAQ: ZYNE) is developing cannabis-based treatments for rare and near-rare neurological disorders. The company is working on transdermal drugs to help patients suffering from fragile X syndrome, certain forms of epilepsy and Tourette’s syndrome.

Cannabis biotech efforts are unleashing a range of new treatments. As more is discovered about the cannabis plant’s potential, treatments for a range of previously hard-to-manage conditions are being found along with better options for widespread illnesses. In providing innovative solutions and new products, the sector is growing in sophistication and strength.

For more information on Lexaria, please visit Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP).

 About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Cannabis Continues to Provide Progress in Medical Sector

CannabisNewsWire Editorial Coverage: The emergence of a legal recreational cannabis sector has drawn attention away from the medical cannabis market. However, many companies continue to move forward in this strong sector, benefiting from extensive research and development work. PreveCeutical Medical, Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is developing new cannabis-based medicines and delivery systems through partnership with researchers in Australia. Invictus MD Strategies Corporation (TSX-V: GENE) (OTC: IVITF) has created a network of profitable growing facilities that allowed the company to pay out a million-dollar dividend in 2016, the first dividend payout by a Canadian cannabis company, and Radient Technologies, Inc. (TSX-V: RTI) is partnering with cannabis companies to produce medical cannabis extracts. Already the owner of a large growing facility, WeedMD, Inc. (TSX-V: WMD) is in the process of creating 610,000 square feet of greenhouse space that will increase its cannabis production from 1,500kg to 33,000kg over two phases of expansion. Wildflower Marijuana, Inc. (SUN: CNX) sells a range of cannabis-based products, including vaporizers and soap, and is set to expand in the lucrative California market through new licenses in Los Angeles.

Recreational Cannabis’s Big Brother

A lot of attention in the cannabis industry is currently focused on the recreational market. A few nations and states, most notably Canada and California, have legalized recreational cannabis or are on the road to legalization. It’s a huge deal commercially, as companies prepare to exploit new markets. But in the background, the medical sector continues to make leaps forward in cannabis use.

Despite tight restrictions limiting research, a number of different medical benefits from cannabis have already been found. Best known are its use in managing chronic pain and alleviating the nausea and vomiting that follow chemotherapy. Some evidence indicates it might also be effective in dealing with neurological problems, including multiple sclerosis and epilepsy. Scientists are also exploring the use of cannabis in treating HIV and AIDS patients, as well as those suffering posttraumatic stress disorder and a range of other ailments. With so much potential, it’s little wonder that medical cannabis companies are examining every opportunity to leverage their presence in the market.

Prevention, Not Just Cure

PreveCeutical Medical, Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is among the companies committed to researching and developing new cannabis-based treatments.

Founded in 2015, PreveCeutical is the creation of Stephen and Kimberly Van Deventer. Entrepreneurs with extensive experience in venture capital and business development, they have been working together since 2009. As the minds behind Cornerstone Global Partners, they supported the emergence of other companies with significant presence in the medical cannabis sector.

The Van Deventers’ involvement in this sector peaked their interest in health and wellness. They started looking into how they could use their business skills in offering new treatments to health-conscious consumers. Their aim was to combine scientific research with the benefits of natural remedies in order to provide the best of both worlds. PreveCeutical was founded to support this objective, with a focus on preventive medicine, as reflected in its name.

PreveCeutical has shown a strong commitment to working with researchers, teaming up with research centers to develop new and improved options for treatment. The company’s early work has focused on acute problems such as cancer, obesity, Type 2 diabetes, pain management and neurological disorders. That initial focus has naturally led to work with cannabis because of the drug’s use in tackling many of these ongoing ailments.

With its organic and nature identical products, PreveCeutical is well oriented to appeal to consumers looking for ethically sourced and effective treatments for diseases that other drugs are struggling to treat.

Research into Cannabinoids

This week marks an important moment in PreveCeutical’s efforts to improve healthcare through cannabis.

In fulfillment of an agreement announced earlier this year, the first in a series of cannabis shipments has been shipped to the Pharmacy Australia Centre for Excellence (PACE) at the University of Queensland. The cannabis flowers and oils have been provided by Aurora Cannabis, Inc. (TSX: ACB) (OTCQX: ACBFF) as part of a deal with PreveCeutical. Grown within Canada’s carefully licensed and increasingly sophisticated cannabis industry, the flowers and oils will be used by PreveCeutical’s Australian researchers to create and improve cannabis treatments.

Such international work is made complicated by the legal status of cannabis, which varies significantly from one country to another, and is tightly controlled even in territories where it can be legally sold. For this one project, the companies have had to obtain licenses for the export of cannabis from Canada and for that cannabis to be brought into Australia for research purposes. Strict standards have to be met for any sort of work on these products.

PreveCeutical’s partnership with Aurora is an important one in that it has the potential to bring considerable benefit for both companies. As part of the deal, Aurora has received rights including the option to either license resulting technology for Canada and Australia or to opt for a royalty arrangement on product sales (http://cnw.fm/8iRlH). This agreement shows faith in PreveCeutical’s ability to provide effective, profitable treatments based on its research.

“We see an important market for cannabis-based products that are more narrowly targeted at specific therapeutic areas but that are higher value add and being involved with initiatives such as PreveCeutical’s is part of our strategy to gain access to these types of products,” said Terry Booth, CEO of Aurora.

Expanding into Australia

To further support its research efforts in Australia, PreveCeutical recently incorporated a new subsidiary in the country (http://cnw.fm/3kcN2).

Led by its director of International Operations, Dr. Maher Khaled, PreveCeutical (Australia) Pty Ltd will work closely with the company’s chief research officer, Dr. Harry Parekh, to advance the company’s goal of providing new health care options based on rigorous research.

This expansion into Australia has been shaped by the country’s strong academic and clinical research, as well as support from government programs. The Australian government supports scientific innovation through a range of programs and incentives, including a research and development tax break. This provides a 43.5 percent tax offset for eligible R&D activities, from which PreveCeutical’s new subsidiary will benefit.

The company’s Australian research program is centered around the Sol-gel system (http://cnw.fm/on3FQ). An innovative drug delivery system, Sol-gel consists of medicine in liquid form that patients administer via the nasal cavity. There, it forms a gel that stays in place, slowly and steadily releasing active ingredients into the bloodstream.

Sol-gel is ideally suited to deliver drugs targeting the brain. When delivered by traditional methods such as pills and injections, medications have to travel through complex bodily systems, slowing down their arrival and resulting in the filtering out of much of the medicine, thereby limiting the effectiveness of a given dose. Sol-gel uses hydrogels and delivery close to the brain to bypass many of these barriers.

Given cannabis’s potential in tackling pain and neurological symptoms, many cannabis-based medicines are likely to target the brain. With Sol-gel, PreveCeutical may be in a strong position to provide one of the most effective delivery systems for a growing class of drugs.

Using Cannabis as a Cure

Many companies are now involved in providing cannabis-based medical treatments.

Invictus MD Strategies (TSX-V: GENE) (OTC: IVITF) has a foothold in the Canadian cannabis market and with an eye to future growth. Founded in 2014, the company has a number of licensed growing facilities and over 250 acres of property ready to be turned into cultivation space. The one-million-dollar dividend it paid out in 2016 was the first dividend payout by a Canadian cannabis company. With a platform that includes ancillary products such as fertilizers and nutrients, the company benefits from all elements of cannabis production.

Radient (TSX-V: RTI) specializes in the extraction of compounds from biological materials through microwave-assisted processing. This patented technology platform lets the company extract the beneficial elements from all manner of plants for use in food, pharmaceuticals, personal care and other products. This includes working with cannabis growers to produce cannabis extracts for medical use.

WeedMD (TSX-V: WMD) is a medical cannabis company with a 26,0000-square-foot growing space in Ontario. A producer of consistently high-quality cannabis, the company is expanding as the Canadian cannabis market grows. The first phase of an ambitious project to expand its growing facilities is currently underway, with the aim of creating 610,000 square feet of greenhouse space. This will increase the company’s cannabis production from 1,500kg to 21,000kg per year, with a goal of reaching 33,000kg with phase two of the expansion program.

Wildflower Marijuana (SUN: CNX) is focused on providing cannabis health and wellness products for the U.S. market. The company sells a range of products using cannabinoids, including vaporizers, capsules and soap. Its recent acquisition of retail and cultivation licenses in Los Angeles may allow the company to expand in the increasingly lucrative California market.

With so many companies providing a diverse range of products and services, the medical cannabis market continues to go strong, even as recreational cannabis draws the headlines.

For more information on PreveCeutical, visit PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H).

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

ChineseInvestors.com, Inc. (CIIX) Doubles Down on Commitment to Cryptocurrency

  • CIIX acquires equipment to participate in cryptocurrency mining; installing AntMiners and ASIC machines in secure datacenter, it intends to explore feasibility of earning coins such as bitcoin and Litecoin
  • Warren Wang, CEO of CIIX, said that the move positions the company to capitalize on the growing blockchain industry; firm already has a daily broadcast on cryptocurrencies and sponsors bitcoin ATM
  • CIIX may add graphical processing units (GPUs) and more mining equipment in the future

ChineseInvestors.com, Inc. (OTCQB: CIIX) is doubling down on its commitment to cryptocurrency. The company recently announced that it has acquired various pieces of equipment, including AntMiners, and installed them inside of a secure datacenter near Seattle. CIIX intends to use this equipment to explore blockchain mining (http://cnw.fm/6QXnU).

CIIX said that, based on initial reports, it believes that cryptocurrency mining will result in a successful venture. If this forecast proves correct, CIIX anticipates ordering 500 or more application specific integrated circuit (ASIC) units. Additionally, the company would consider purchases of graphical processing units (GPUs) and other equipment used for blockchain mining.

The goal of these efforts is to achieve minimum hash rates that are consistent with the equipment specifications by the end of CIIX’s fiscal year on May 31, 2018. ASIC chips are seen as the ‘hashing workhorses’ of AntMiner units (http://cnw.fm/4cVVi).

CIIX is a company focused on educating and informing its global Chinese-speaking audience on a variety of financial subjects. It also has a core consulting business that manages brand building and roadshows for clients.

Prior to this new focus on the exploration of actual cryptocurrency blockchain mining, CIIX had already assumed a leadership position in this industry. It hosts a bitcoin ATM in the lobby of its San Gabriel, California, headquarters. It also broadcasts a daily video from the floor of the NYSE, titled ‘Bitcoin MultiMillionaire’, reporting on cryptocurrency news. Additionally, CIIX maintains an online crypto news website at www.NewCoins168.com.

In a news release, Warren Wang, CEO of CIIX, explained, “The Company endeavors to be on the cutting edge of blockchain technology and to stay ahead of the curve in an effort to continue to build shareholder value and increase revenues this year… This initial step into cryptocurrency mining positions the company to capitalize on a growing industry which could have tremendous upside potential.”

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Helping Smokers Light Up Less

  • Poised to revolutionize smokeless tobacco
  • Proven effective in cannabinoid delivery, undergoing testing for nicotine
  • An enabling tech seeking third-party partnerships within the tobacco industry

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is helping smokers light up less. Using LXRP’s revolutionary technology, smokers could be able to give up smoking without giving up nicotine. With one billion smokers worldwide, companies are seeking safer delivery technologies to help wean smokers from this deadly habit. Through third-party partnerships with major tobacco industry players, LXRP is poised to revolutionize smokeless tobacco (http://cnw.fm/YP8jF).

Lexaria is gaining prominence for its proprietary delivery technology. The company’s DehydraTECH™ technology, already proven effective in cannabinoid delivery, is undergoing testing for nicotine. Smoking is harmful due to the 4,000 chemicals released when the tobacco is lit up, even though the amount of nicotine absorbed by smokers represents a minimal hazard. Inhalation through the lungs is not healthy. Non-combusted food and drink through the human GI have been found to be much safer. However, previous methods of infusing tobacco in gum, mints or coffee have irritated the gastrointestinal tract, creating cramps and other symptoms, and required sweeteners to mask the bitter taste.

LXRP’s technology enables the delivery of bioactive substances via oral ingestion without the need for the unhealthy practice of inhalational dosing or the addition of unhealthy sugars or sweeteners. In addition, DehydraTECH acts as a Trojan horse, allowing the drug to enter the GI tract, and it is expected to reduce or eliminate uncomfortable side effects that smokers have experienced through previous edible food formats. DehydraTECH is powerful at accelerating intestinal absorption, having already been proven to decrease delivery-time to the bloodstream of edible cannabinoids from the previous 60-90 minutes to a mere 10-15 minutes.

Following its established model in the cannabis industry, Lexaria’s aim is to partner with tobacco companies rather than compete with them. It is an enabling tech, not a competing tech. In the cannabis industry, the company has entered into a licensing agreement with Biolog, Inc. (a Utah-based company not to be confused with a California cell phenotyping company of the same name) to create a unique set of next-generation food and beverage cannabis-infused products for the U.S. market. LXRP also recently entered into an agreement with Cannfections Group Inc. to create cannabis-infused chocolates and candies for the Canadian market.

Lexaria is now looking to out-license its DehydraTECH to third-party partners in the tobacco industry. These partnerships could pave the way for a healthier smoke-free option for the one billion smokers worldwide. Lexaria is the only company in the world that holds a patent for this oral technology, including the pill. A new U.S. patent award protects this nicotine delivery system, creating a path for what could be the world’s first nicotine edibles for the smokeless tobacco industry.

For more information, visit the company’s website at www.LexariaBioscience.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

CannabisNewsBreaks – Global Payout, Inc. (GOHE) Subsidiary Attends Cali-Baja Israel Mexico Innovation Expo

Payment solutions company Global Payout, Inc. (OTC: GOHE), through majority-owned subsidiary MoneyTrac Technology, Inc. (“MTRAC”), this morning announced its attendance at the Cali-Baja Israel Mexico Innovation Expo in Tijuana on March 20-21. Per the update, MTRAC provided key representational support for its partner, GreenBox, at the event, capitalizing on the opportunity to share the forward-thinking blockchain technology solutions offered by GreenBox with leaders from a wide range of industries. “The primary objective of attending this expo in partnership with GreenBox was to further our efforts in helping them develop their brand image and generate additional buzz for the impressive blockchain technology-based solutions they are prepared to deliver to a variety of target market sectors,” Vanessa Luna, CEO of MTRAC, stated in the news release. “I am very encouraged by the interest and overall excitement we received during the expo especially in knowing that it was received from individuals who are innovators and leaders in the world of technology solutions. My team and I recognize now more than ever the disruptive capabilities GreenBox can infuse into multiple high-cost banking industries and truly be a driving force behind bringing our mission of Banking the Unbankable to fruition.”

To view the full press release, visit http://cnw.fm/W97eV

About Global Payout, Inc.

Since the Company’s inception in 2009, Global Payout, Inc. has been a leading provider of comprehensive and customized prepaid payment solutions for domestic and international organizations distributing money worldwide. In 2014, Global introduced its first online payment platform called the Consolidated Payment Gateway (CPG), which allowed its enterprise clients to transfer money to international bank accounts, mobile accounts, and prepaid card accounts. The development of the CPG became the foundation for the introduction of its new, state of the art FINTECH payment system in 2017, for both online and mobile applications to allow account holders to maximize an expanded suite of financial services and minimize operational costs. Global will continue to offer their FINTECH payment system to many vertical markets for support of foreign currency exchange and digital currency, including ongoing support of the banking industry and international governments. For more information, visit www.GlobalPayout.com

More from CannabisNewsBreaks

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Marijuana Company of America, Inc. (MCOA) Provides Turnkey Services to Hemp Growers

  • Hemp cultivation in the U.S. is on the rise
  • 33 U.S. states have dismantled barriers to hemp production
  • MCOA provides turnkey services to growers and distributors

Hemp is back! After a hiatus of 77 years, cultivation of hemp in the U.S. began again after the passage of the Farm Bill in 2014. The Farm Bill allows departments of agriculture and institutions of higher learning in states that have legalized hemp cultivation to grow hemp for research and pilot programs. Hemp grown for such purposes is now no longer subject to the provisions of the Controlled Substances Act (CSA), although, unfortunately, commercial cultivation still is. Despite the continued federal restriction on growing hemp, a majority of states (33) have dismantled barriers to hemp production, and U.S. hemp output doubled from 2016, with about 1,500 state hemp cultivation licenses being issued in 2017. These growers can turn to Marijuana Company of America, Inc. (OTC: MCOA) to get their enterprises off the ground. The company provides turnkey services to the legal cannabis and hemp industries. It also, through wholly owned subsidiary hempSMART™, delivers all of the benefits of hemp-derived cannabinoid (CBD) products to the world through its unique marketing and distribution platform.

The domestic network of hemp farmers and cultivars is set to expand as regulations ease. For example, research has shown that, instead of graphene, hemp bast fiber may be used in super-capacitor batteries to power electric vehicles (EVs) and handheld electric devices and tools. In addition, hemp fiber has long been a staple of housing construction in some cultures; now, it’s building American homes. Hemp houses are on the rise, as hempcrete, which is energy-efficient, non-toxic and resistant to mold, insects and fire, has many advantages over synthetic building materials, lumber and concrete. Hemp fiber can also be used to create environmentally friendly composites and hard bio-plastics for use in everything from airplanes to car parts.

Hemp seeds are also one of the fastest-growing categories in the natural foods industry. A rich source of Omega-3 and Omega-6 essential fatty acids (EFAs), these seeds provide both stearidonic acid (SDA) and gamma-­linoleic acid (GLA), as well as naturally occurring vitamins and minerals, such as vitamin E and iron. Hemp seeds are also an excellent source of dietary fiber and a complete protein, containing all 10 essential amino acids with no enzyme inhibitors, which makes them more digestible by the human body.

Through wholly owned subsidiary hempSMART™, MCOA is bringing high quality CBD-based products derived from industrial hemp to market through its affiliate marketing program. Its patent-pending product, hempSMART Brain, provides safe and effective support of healthy brain function, while its recently launched HempSMART DROPS is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The company recently debuted its new encapsulate product, hempSMART Pain, formulated with 10mg of full spectrum, non-psychoactive CBD per serving, which, along with a proprietary blend of other natural ingredients, delivers an all-natural formulation for the temporary relief of minor pain associated with physical activity.

MCOA has also collaborated with the founders of HoneyB Healthy Living to develop Convenient Hemp Mart, LLC’s BeniHemp-branded products targeting convenience stores. The brand was officially launched at the recent ASD Market Week (March 11-14, 2018) business trade show in Las Vegas (http://cnw.fm/G74iX). Convenient Hemp Mart has developed a collection of Benihemp-branded, sample-sized products for consumers, including topicals, tinctures and edibles packaged in 1-day, 2-day, and 30-day supplies. The target markets for these offerings are convenience stores, smoke shops, gas stations and similar types of retail businesses where CBD commerce has a greater likelihood of generating sales from the impulse buyer at the register.

As legitimization of the hemp industry progresses, Marijuana Company of America has positioned itself at various points in the value chain. The company not only markets a wide range of hemp-derived CBD products; it also provides turnkey services for marketers and growers alike.

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Compensation Disclosure

Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment. In order to be in full compliance with the Securities Act of 1933, Section 17(b), we are disclosing that we entered into a contract with Marijuana Company of America, Inc. The Company agreed to compensate us with $5,000 USD a month for our services.

Medical Cannabis Payment Solutions (REFG) Now Available To Entire Legal Cannabis Industry

  • REFG fully launched its payment system services to the entire industry
  • Technology is fully FinCEN-compliant
  • Bitcoin payments are on the horizon with Green

 Medical Cannabis Payment Solutions (OTC: REFG) seeks to provide end-to-end management for medicinal marijuana operations. The company serves the medical cannabis and banking industries through state-of-the-art comprehensive card processing operations, and it has now fully launched its payment system services to the entire legal cannabis industry. The company previously worked only with targeted industry establishments, but its platform is now available to all state-sanctioned establishments in the U.S. and abroad. The company is the first of its kind, empowering cannabis businesses with an advanced client management system that tracks both sales and tax collection. REFG has solved the problem of banking and cashless payments within the cannabis industry.

The company offers electronic payment and e-commerce features that allow businesses direct and immediate access to funds. One of the advantages of using REFG’s top-tier digital payment processing system, Green, is its compliancy with FinCEN. The system tracks sales and tax collection while providing businesses with an advanced client management system. If a business is called on to prove compliance with financial regulations within the cannabis industry, the company cooperates with authorities and defends the client’s interests.

In addition, Green provides cannabis retailers and consumers with payment options other than cash. Consumers can purchase items using U.S. currency, and they will soon be allowed to pay with bitcoin. In November 2017, REFG announced that integration with First Bitcoin Capital’s Weed Coin cryptocurrency and StateSourced’s medical cannabis payment gateway services will soon enable cryptocurrency payments. This will increase the ease of payment and cash handling in the cannabis industry and will allow consumers to overcome many regulatory obstacles.

With growing trends toward widespread legalization, both in the U.S. and abroad, REFG is strategically positioned for growth as the only company on the market that’s currently offering a completely integrated payment processing system tailored to the cannabis industry.

For more information, visit the company’s website at www.MedicalCannabisPaymentSolutions.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) Signs Deal to Open Multiple Choom™ Branded Retail Dispensaries

  • Choom™ is a high-quality hand-crafted cannabis brand created for the Canadian recreational market
  • Last month, the company opened retail opportunity to entrepreneurs and businesspeople across Canada
  • Choom™ inked first deal, not for just a single store, but rather for an entire territory

Set to be legalized in July of this year, Canada’s recreational marijuana market is estimated to exceed $8.7 billion annually. That figure doesn’t include ancillary businesses such as paraphernalia, weed-related tourism, testing labs and security services. All factored in, the market potential jumps to up to $22.6 billion a year (http://cnw.fm/h2lwW). The general consensus is that the marijuana market in Canada will only continue along an upward trajectory. Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) is rapidly positioning itself to become the premier recreational cannabis brand in Canada and capture a significant portion of this newfound cannabis bonanza.

Choom™ is a high-quality hand-crafted cannabis brand created exclusively for the Canadian recreational market. By cultivating outstanding bud as well as an exceptional customer experience, Choom™ intends to become the recognized market leader in reaching the cannabis consumer. To achieve that end, Choom™ is developing a chain of modern, stylish dispensaries designed by the same team responsible for some of the most desirable retail environments in Canada. The company has expanded the opportunity to entrepreneurs and businesspeople interested in participating in the lucrative new recreational marijuana market by registering for their own Choom™ stores.

Announced only about a month ago (http://cnw.fm/QV1av), the response to owning a Choom™ store is exceeding expectations, as savvy business folks are lining up for a piece of the cannabis pie. This comes as little surprise, since legal recreational marijuana dispensaries are expected to generate more revenue per square foot than Whole Foods. In line with this response, the company recently announced that it has signed the first agreement in its retail investor program (http://cnw.fm/Er5eq).

Following its bold agenda, Choom™ has inked a deal not for just a single store but rather for an entire territory. A consortium of local investors and business partners known as the ‘Thompson Okanagan Choom Group’ has secured the exclusive territory rights to open multiple Choom™ branded retail dispensaries in the Thompson-Okanagan region. The Thompson-Okanagan region is a tourist magnet located in the central interior of British Columbia and offers wineries, boating and loads of outdoor activities. The investment consortium is led by Debra G. Adams, Sherman Dahl, Imre Kovacs and Kent Adams, all of whom are excited about the Choom™ opportunity. In a news release, Adams stated, “We’ve been closely monitoring the explosion of Cannabis companies in Canada and are very pleased to be working with a ‘best in class’ operator such as Choom™. The branding, professionalism and style of Choom™ is second to none and our team can’t wait to get started!”

By cultivating outstanding bud as well as an exceptional consumer experience, Choom™ is likely to attract evermore retail partners and is fast on its way to establishing a significant retail footprint and becoming a recognized leader in the Canadian recreational cannabis markets.

For more information, visit the company’s website at www.Choom.ca

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) Seeking its Share in the Anticipated Canadian Recreational Marijuana Market

  • Potential Canadian marijuana market upside estimated at $22.6 billion
  • Choom™ strategy is soil-to-shelf integration through cultivation, branding and retail marketing
  • Company seeking phase 1 and 2 revenue growth in Vernon and Vancouver Island, British Columbia, Canada

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) is focused on the recreational marijuana market in Canada and is projecting revenues from its retrofit and expansion efforts in Vernon and Vancouver Island, British Columbia, Canada. In its investor presentation of March 2018 (http://cnw.fm/pER7I), the company positioned itself to become a branded, fully integrated cannabis company in the recreational marijuana market of Canada. Its plans for growth include its own product cultivation, retail expansion and acquisitions.

In its presentation, Choom quotes the ‘Canaccord Genuity Canadian Cannabis Industry Overview’ as projecting that the total marijuana market will reach $6 billion by 2021. It finds that recreational users will outnumber medical marijuana users by almost eight times, calling for 3.8 million recreational users to roughly 500,000 medical users.

The Vancouver-based company is focused on branding, building a chain of its own Choom retail dispensaries, positioning its premium brand and acquiring production assets.

Choom has two significant projects. Through its presence in Vernon, British Columbia, it expects phase 1 revenue of $6.6 million, with $15 million from phase 2. A retrofit is scheduled for completion by July 2018, and expansion is planned for the end of 2018. In Vancouver Island, British Columbia, phase 1 potential revenue is estimated at $4.5 million, with $9 million in phase 2. All revenue projects exclude oils. Retrofit completion is scheduled for July 2018, and phase 2 expansion completion is planned by the end of 2019.

The larger picture focuses on the total marijuana market’s potential upside of $22.6 billion, according to the Deloitte Recreational Marijuana/Insights and Opportunities report (http://cnw.fm/ii5J6). This upside figure represents the additional revenue from growers, tourism, license fees, business taxes and base retail market value.

As it grows, Choom’s shares are now Depository Trust Company (“DTC”) of New York-eligible, allowing for easier trading of Choom shares on the OTC (http://cnw.fm/v72CO). The company recently named Chris Gagan as its senior vice president of marketing, making him responsible for the development of the Choom brand and retail marketing (http://cnw.fm/Nh6hM).

For more information, visit the company’s website at www.Choom.ca

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Nevada Eyes Denver’s New Pot Lounges, Las Vegas to Come to the Table in 2019

  • Denver presents the first recreational cannabis lounges
  • Las Vegas officials cautious about pot lounge endeavors until 2019 legislative meetings
  • Pilot projects in effect to weigh pros and cons of new recreational marijuana use

Denver’s first social-use marijuana permit was awarded to The Coffee Joint in early March of this year, establishing it as the first of what looks to be many pot consumption lounges to open in the coming years. Denver’s cannabis consumption establishment makes allowance for those who are over 21 to consume legal quantities of pot through methods of consuming edible products, vaping and dabbing within the venue itself, with the sole exclusion of smoking only being allowed outdoors (http://cnw.fm/YXa0Q).

City officials in Las Vegas are currently waiting on the City of Denver to approve the country’s first marijuana club, prior to their own discussions revolving around the licensing and regulation of lounges dedicated to marijuana within Las Vegas. With Nevada having permitted the lawful sale of recreational marijuana in July of 2017, a great demand has been placed on related commercial industries brought by the tourists that visit the state. The law mentions, however, that no public consumption of the substance is allowed outside of private residences.

In a public meeting following discussions around the opening of pot lounges, Commissioner James Gibson of Clark County, Nevada, said, “I don’t know if we need to be the first or not, I don’t see any reason why we have to be first, but we certainly have to be right.” Gibson went further to say that regardless of what happens, officials need to do their part and remain consistent through implementation of thorough procedures.

Denver’s announcement in August of 2017 allowed for the submission of applications by businesses that are looking to open marijuana clubs. Up until now, there have been few developments in this regard, with the slow start having been expected because of overly extensive application procedures. “What I have heard from the commission today is that they are open to the idea in concept, but they are not ready to move forward,” added Andrew Jolly, storeowner and president of the Nevada Dispensary Association. Jolly mentioned further that the presentation of a pilot project is the intention. This process would then critically highlight several pros and cons regarding the matter at hand.

As mentioned in the Las Vegas Sun, both the Las Vegas City Council and the Clark County commission have taken a ‘wait-and-see approach’, this being the first notable time that any timeframe of the endeavor had been given. As the situation currently stands, industry advocates have had their eyes on public lounges for consumption since the start of recreational sales last July. It is with the notion of over 40 million tourists entering Nevada each year, with the restrictions on cannabis consumption severely limiting use within hotels and casinos.

The Clark County Commission is currently planning to wait on public consumption of marijuana until the 2019 state legislature meetings. Chris Giunchigliani, county commissioner, urged that his group first wants to monitor the social use implementation in Denver prior to any decisions on their part (http://cnw.fm/eF4sX).

State Senator Tick Segerblom put forth his disappointment in that his vision of Las Vegas being the first major city within the United States to open marijuana lounges did not come to fruition. The step taken by Denver was noted to be a step forward, with the potential of benefiting Nevada. A further step forward would see the allowance of smoking the substance within lounges, with consumers not necessarily being restricted to consuming edible products, vaping and dabbing, as is the case in Colorado. It is with great anticipation that Las Vegas is awaiting the 2019 legislature meetings to prove successful within the recreational cannabis consumption industry.

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net